Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Pazopanib is a potent multitargeted tyrosine kinase inhibitor that has been shown to have good efficacy in patients with renal cell carcinoma. A previous phase II trial demonstrated that short-term pazopanib administration was generally well tolerated and showed antitumor activity in patients with early-stage non-small cell lung cancer. Herein, we report on the case of a 66-year-old man with simultaneous metastatic squamous cell carcinoma of the lung and renal cell carcinoma who was treated with pazopanib. The patient showed an unexpected partial response and experienced a 10-month progression-free survival without significant toxicity. To the best of the authors’ knowledge, this is the first report of pazopanib treatment in a non-small cell lung cancer patient in Korea. The results in this patient suggest that pazopanib may be a valid treatment option for advanced non-small cell lung cancer.
Abstract
Pazopanib is a potent multitargeted tyrosine kinase inhibitor that has been shown to have good efficacy in patients with renal cell carcinoma. A previous phase II trial demonstrated that short-term pazopanib administration was generally well tolerated and showed antitumor activity in patients with early-stage non-small cell lung cancer. Herein, we report on the case of a 66-year-old man with simultaneous metastatic squamous cell carcinoma of the lung and renal cell carcinoma who was treated with pazopanib. The patient showed an unexpected partial response and experienced a 10-month progression-free survival without significant toxicity. To the best of the authors’ knowledge, this is the first report of pazopanib treatment in a non-small cell lung cancer patient in Korea. The results in this patient suggest that pazopanib may be a valid treatment option for advanced non-small cell lung cancer.
참고문헌 (15)
- Mulshine JL, "Clinical practice. Lung cancer screening", N Engl J Med, 352, pp.2714~2720 (2005)
- Sternberg CN, "Pazopanib in locally advanced or metastatic renal cell carcinoma : results of a randomized phase III trial", J Clin Oncol, 28, pp.1061~1068 (2010)
- van der Graaf WT, "Pazopanib for metastatic soft-tissue sarcoma(PALETTE) : a randomised, double-blind, placebocontrolled phase 3 trial", Lancet, 379, pp.1879~1886 (2012)
- Altorki N, "Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I", II resectable non-small-cell lung cancer, 2010, pp.28, 3131~3137
- Bible KC, "A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma : MC057H", J Clin Endocrinol Metab, 99, pp.1687~1693 (2014)
- Ettinger DS, "Non-small cell lung cancer", J Natl Compr Canc Netw, 8, pp.740~801 (2010)
- Fukuoka M, "Biomarker analyses and final overall survival results from a phase III, randomized, openlabel, first-line study of gefitinib versus carboplatin", paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia(IPASS), 2011, pp.29, 2866~2874
- Cappuzzo F, "Erlotinib as maintenance treatment in advanced non-small-cell lung cancer : a multicentre, randomised, placebo-controlled phase 3 study", Lancet Oncol, 11, pp.521~529 (2010)
- Santoni M, "Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors : a systematic review and meta-analysis of clinical trials", Int J Cancer, 135, pp.763~773 (2014)
- Majem M, "An update on molecularly targeted therapies in second-and third-line treatment in non-small cell lung cancer : focus on EGFR inhibitors and anti-angiogenic agents", Clin Transl Oncol, 15, pp.343~357 (2013)
- Barlesi F, "Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer : AVAPERL(MO22089)", J Clin Oncol, 31, pp.3004~3011 (2013)
- Ganjoo KN, "A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors(GIST)following failure of at least imatinib and sunitinib", Ann Oncol, 25, pp.236~240 (2014)
- Ahn HK, "Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours", Br J Cancer, 109, pp.1414~1419 (2013)
- Hurwitz HI, "Phase I trial of pazopanib in patients with advanced cancer", Clin Cancer Res, 15, pp.4220~4227 (2009)
- Dy GK, "Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib", Invest New Drugs, 31, pp.891~899 (2013)